Category: Corona Virus Vaccine

Page 16«..10..15161718..3040..»

Scientists argue over the origins of COVID-19 before U.S. Senate panel Wisconsin Examiner – Wisconsin Examiner

June 25, 2024

WASHINGTON Scientists debated the origins of COVID-19 on Tuesday, trading barbs over whether the bulk of evidence available points to a natural spillover event from a wild animal or a virus designed in a lab and then let loose through an inadvertent leak.

The hearing in front of the U.S. Senate Homeland Security and Governmental Affairs Committee was part of ongoing efforts in Congress to apply the lessons learned during the pandemic to prevent or blunt the next outbreak.

Gregory Koblentz, associate professor and director of the Biodefense Graduate Program at George Mason University in Virginia, said during the two-hour hearing that debate continues in the scientific community about the origins.

The possibility that SARS-CoV-2 was deliberately developed as a biological weapon has been unanimously rejected by all U.S. intelligence agencies, Koblentz testified. While the intelligence community is divided on the origin of the pandemic, most of the agencies have determined that the virus was not genetically engineered.

Residents in Wuhan, China, were first diagnosed with an atypical pneumonia-like illness in December 2019, according to a COVID-19 timeline from the Centers for Disease Control and Prevention.

Initial cases all appeared linked to the Huanan Seafood Wholesale Market at the time, though there has since been much speculation about the types of research taking place at the Wuhan Institute of Virology.

Koblentz said he believes the available evidence points to a spillover event from an animal, though he added a research-related accident cant be ruled out at this time.

The lack of transparency and data from the Chinese government has significantly hindered scientists efforts to unify around the origin of COVID-19, he said.

Richard Ebright, board of governors professor of chemistry and chemical biology and laboratory director at the Waksman Institute of Microbiology at Rutgers University in New Jersey, testified he believes a large preponderance of evidence indicates SARS-CoV-2, the virus that causes COVID-19, entered humans through a research incident.

Ebright also leveled criticism at fellow panelist Robert Garry, who, along with a handful of co-authors, published an opinion article in the journal nature medicine in March 2020, titled The proximal origin of SARS-CoV-2.

In the commentary, Garry and the other scientists wrote, we do not believe that any type of laboratory-based scenario is plausible.

Ebright said during Tuesdays hearing that the opinion article represented scientific misconduct up to and including fraud, a characterization that Garry rejected during the hearing.

The authors were stating their opinion, but that opinion was not well-founded, Ebright said. In March of 2020, there was no basis to state that as a conclusion, as opposed to simply being a hypothesis.

Garry, professor and associate dean of the School of Medicine at Tulane University in Louisiana, argued on behalf of the spillover event during the hearing, testifying that the virus likely didnt move directly from a bat to humans, but went to an unidentified intermediary animal.

The bat coronaviruses are viruses that are spread by the gastrointestinal route, Garry said. For a virus like this to become a respiratory virus its just going to require too many mutations, too many changes for a bat virus to spill directly over to a human being. That could only really happen in nature with replication through an intermediate animal.

Garry also defended gain-of-function research during the hearing, arguing that it has had some beneficial impact, though he noted that it does need appropriate safeguards and restrictions.

Lawmakers and pundits have used several, often evolving, definitions for gain-of-function research in the wake of the COVID-19 pandemic. The American Society for Microbiology defines it as techniques used in research to alter the function of an organism in such a way that it is able to do more than it used to do.

When research is responsibly performed on highly transmissible and pathogenic viruses, it can lead to advances in public health and national security, Garry testified.

Without gain-of-function research, wed have no Tamiflu. Without gain-of-function research, we wouldnt have a vaccine to prevent cancer caused by infection by the human papilloma virus, Garry said. And without gain-of-function research, we wont be able to identify how novel viruses infect us. And if we dont know how they infect us, we cannot develop appropriate treatments and cures for the next potential pandemic creating virus.

New Hampshire Democratic Sen. Maggie Hassan raised several questions about whether theres enough oversight of how the United States spends research dollars as well as what mechanisms are in place to monitor how private entities conduct certain types of research.

While their research has the potential to cure diseases and boost our economy, unless they accept federal funding, there is very little federal oversight to ensure that private labs are engaged in safe and ethical research, she said.

Koblentz from George Mason University said there is much less oversight of biosafety and biosecurity for private research facilities that dont receive federal funding.

In order to expand the scope of oversight to all privately funded research, (it) would require legislative action, Koblentz said.

Congress, he said, should establish a national bio-risk management agency that would have authority over biosafety and biosecurity regardless of the source of funding.

At the end of the day, it shouldnt matter where the funding comes from in terms of making sure this research is being done safely, securely and responsibly, Koblentz said.

Kentucky Republican Sen. Rand Paul, ranking member on the committee, said the panel will hold an upcoming hearing specifically on gain-of-function research, including what steps Congress should take to ensure it doesnt put the public at risk.

Committee Chairman Gary Peters, a Michigan Democrat, said during the hearing that lawmakers must learn from the challenges faced during this pandemic to ensure we can better protect Americans from future potential biological incidents.

Our government needs the flexibility to determine the origins of naturally occurring outbreaks, as well as potential outbreaks that could arise from mistakes or malicious intent, Peters said.

Utah Republican Sen. Mitt Romney, after listening to some of the debate, expressed exasperation that so much attention is going toward what caused the last pandemic and not on how to prepare for the next one.

Given the fact that it could have been either, we know what action we ought to take to protect from either, Romney said. And so why theres so much passion around that makes me think its more political than scientific, but maybe Im wrong.

The United States, he said, shouldnt be funding gain-of-function research and should insist that anyone who receives federal funding follow the standards of the International Organization for Standardization.

GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX

SUBSCRIBE

Go here to read the rest:

Scientists argue over the origins of COVID-19 before U.S. Senate panel Wisconsin Examiner - Wisconsin Examiner

Study finds "high likelihood" of link between COVID-19 vaccines and deaths in vaccinated people – Voz Media

June 25, 2024

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

The rest is here:

Study finds "high likelihood" of link between COVID-19 vaccines and deaths in vaccinated people - Voz Media

Getting boosted with newer COVID-19 vaccines reduces your risk of ending up in hospital – Scimex

June 25, 2024

Embargoed until: Publicly released: 2024-06-25 01:00

The updated Pfizer COVID-19 vaccines targeting the XBB variant are 62% effective at preventing COVID-19-related hospitalisation, compared to being unvaccinated or only receiving the original vaccines, according to international researchers who say continued booster shots are likely important for people across a broad age range. The researchers looked at US data on COVID-19 hospitalisations in late 2023 and vaccination histories, and say there was no clear difference in risk for unvaccinated people and those who'd only received the original vaccines. In an accompanying editorial, independent researchers say it is difficult now to untangle whether the protection is coming from getting the newer vaccine, or simply getting boosted more recently and it is likely both vaccinated and unvaccinated people have some baseline immunity now the virus has been circulating so long.

Journal/conference: JAMA Internal Medicine

Link to research (DOI): 10.1001/jamainternmed.2024.1640

Organisation/s: Kaiser Permanente Southern California, USA

Funder: This study was sponsored by Pfizer.

About The Study:The findings of this case-control study reaffirm current recommendations for broad age-based use of annually updated COVID-19 vaccines given that (1) the BNT162b2 XBB vaccine (Pfizer-BioNTech; 2023-2024 formulation) provided statistically significant additional protection againsta range of COVID-19 outcomes and (2) older versions of COVID-19 vaccines offered little, if any, long-term protection, including against hospital admission, regardless of the number or type of prior doses received.

Note: Not all attachments are visible to the general public

Original post:

Getting boosted with newer COVID-19 vaccines reduces your risk of ending up in hospital - Scimex

India’s First Indigenous COVID-19 Vaccine Resolves Unintentional Omission – Precision Vaccinations

June 25, 2024

Hyderabad (Precision Vaccinations News)

Bharat Biotech International Limited (BBIL) recently statedX thatthe company unintentionallyomitted the Indian Council of Medical Research (ICMR) as a co-owner of the inactivated COVAXINvaccine patent.

On June 22, 2024, the Hyderabad-based vaccine producer Tweeted that it was taking legal action to correct this issue.

According to media reporting, ICMR was to receive a 5%royalty on net sales and product branding rights, which include 'co-inventor' status.

COVAXINwas developed from a SARS-CoV-2 coronavirus strain isolated at the National Institute of Virology, under the ICMR. The government health research agency also supported the vaccine's clinical development through assistance in conducting clinical trials.

This non-mRNAvaccine wasdeveloped usingWhole-Virion Inactivated Vero Cell-derived platform technology.

During the initial stages of the recent pandemic, the World Health Organization Listed the COVAXIN vaccine as effective in November 2021.

BBIL says inactivated vaccines do not replicate and are unlikely to revert and cause pathological effects. They contain dead viruses, incapable of infecting people but still able to instruct the immune system to mount a defensive reaction against an infection.

However,a report published inSpringer Nature in August 2023found certain people wereat a higher risk of adverse events after receiving COVAXIN.

As of June 2024, COVAXIN is available in about 14 countries, but not the United States.

Read more from the original source:

India's First Indigenous COVID-19 Vaccine Resolves Unintentional Omission - Precision Vaccinations

Supreme Court rejects COVID-19 vaccine appeals from nonprofit founded by Robert F. Kennedy Jr. – Bowling Green Daily News

June 25, 2024

State Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington Washington D.C. West Virginia Wisconsin Wyoming Puerto Rico US Virgin Islands Armed Forces Americas Armed Forces Pacific Armed Forces Europe Northern Mariana Islands Marshall Islands American Samoa Federated States of Micronesia Guam Palau Alberta, Canada British Columbia, Canada Manitoba, Canada New Brunswick, Canada Newfoundland, Canada Nova Scotia, Canada Northwest Territories, Canada Nunavut, Canada Ontario, Canada Prince Edward Island, Canada Quebec, Canada Saskatchewan, Canada Yukon Territory, Canada

Zip Code

Country United States of America US Virgin Islands United States Minor Outlying Islands Canada Mexico, United Mexican States Bahamas, Commonwealth of the Cuba, Republic of Dominican Republic Haiti, Republic of Jamaica Afghanistan Albania, People's Socialist Republic of Algeria, People's Democratic Republic of American Samoa Andorra, Principality of Angola, Republic of Anguilla Antarctica (the territory South of 60 deg S) Antigua and Barbuda Argentina, Argentine Republic Armenia Aruba Australia, Commonwealth of Austria, Republic of Azerbaijan, Republic of Bahrain, Kingdom of Bangladesh, People's Republic of Barbados Belarus Belgium, Kingdom of Belize Benin, People's Republic of Bermuda Bhutan, Kingdom of Bolivia, Republic of Bosnia and Herzegovina Botswana, Republic of Bouvet Island (Bouvetoya) Brazil, Federative Republic of British Indian Ocean Territory (Chagos Archipelago) British Virgin Islands Brunei Darussalam Bulgaria, People's Republic of Burkina Faso Burundi, Republic of Cambodia, Kingdom of Cameroon, United Republic of Cape Verde, Republic of Cayman Islands Central African Republic Chad, Republic of Chile, Republic of China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia, Republic of Comoros, Union of the Congo, Democratic Republic of Congo, People's Republic of Cook Islands Costa Rica, Republic of Cote D'Ivoire, Ivory Coast, Republic of the Cyprus, Republic of Czech Republic Denmark, Kingdom of Djibouti, Republic of Dominica, Commonwealth of Ecuador, Republic of Egypt, Arab Republic of El Salvador, Republic of Equatorial Guinea, Republic of Eritrea Estonia Ethiopia Faeroe Islands Falkland Islands (Malvinas) Fiji, Republic of the Fiji Islands Finland, Republic of France, French Republic French Guiana French Polynesia French Southern Territories Gabon, Gabonese Republic Gambia, Republic of the Georgia Germany Ghana, Republic of Gibraltar Greece, Hellenic Republic Greenland Grenada Guadaloupe Guam Guatemala, Republic of Guinea, Revolutionary People's Rep'c of Guinea-Bissau, Republic of Guyana, Republic of Heard and McDonald Islands Holy See (Vatican City State) Honduras, Republic of Hong Kong, Special Administrative Region of China Hrvatska (Croatia) Hungary, Hungarian People's Republic Iceland, Republic of India, Republic of Indonesia, Republic of Iran, Islamic Republic of Iraq, Republic of Ireland Israel, State of Italy, Italian Republic Japan Jordan, Hashemite Kingdom of Kazakhstan, Republic of Kenya, Republic of Kiribati, Republic of Korea, Democratic People's Republic of Korea, Republic of Kuwait, State of Kyrgyz Republic Lao People's Democratic Republic Latvia Lebanon, Lebanese Republic Lesotho, Kingdom of Liberia, Republic of Libyan Arab Jamahiriya Liechtenstein, Principality of Lithuania Luxembourg, Grand Duchy of Macao, Special Administrative Region of China Macedonia, the former Yugoslav Republic of Madagascar, Republic of Malawi, Republic of Malaysia Maldives, Republic of Mali, Republic of Malta, Republic of Marshall Islands Martinique Mauritania, Islamic Republic of Mauritius Mayotte Micronesia, Federated States of Moldova, Republic of Monaco, Principality of Mongolia, Mongolian People's Republic Montserrat Morocco, Kingdom of Mozambique, People's Republic of Myanmar Namibia Nauru, Republic of Nepal, Kingdom of Netherlands Antilles Netherlands, Kingdom of the New Caledonia New Zealand Nicaragua, Republic of Niger, Republic of the Nigeria, Federal Republic of Niue, Republic of Norfolk Island Northern Mariana Islands Norway, Kingdom of Oman, Sultanate of Pakistan, Islamic Republic of Palau Palestinian Territory, Occupied Panama, Republic of Papua New Guinea Paraguay, Republic of Peru, Republic of Philippines, Republic of the Pitcairn Island Poland, Polish People's Republic Portugal, Portuguese Republic Puerto Rico Qatar, State of Reunion Romania, Socialist Republic of Russian Federation Rwanda, Rwandese Republic Samoa, Independent State of San Marino, Republic of Sao Tome and Principe, Democratic Republic of Saudi Arabia, Kingdom of Senegal, Republic of Serbia and Montenegro Seychelles, Republic of Sierra Leone, Republic of Singapore, Republic of Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia, Somali Republic South Africa, Republic of South Georgia and the South Sandwich Islands Spain, Spanish State Sri Lanka, Democratic Socialist Republic of St. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Vincent and the Grenadines Sudan, Democratic Republic of the Suriname, Republic of Svalbard & Jan Mayen Islands Swaziland, Kingdom of Sweden, Kingdom of Switzerland, Swiss Confederation Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand, Kingdom of Timor-Leste, Democratic Republic of Togo, Togolese Republic Tokelau (Tokelau Islands) Tonga, Kingdom of Trinidad and Tobago, Republic of Tunisia, Republic of Turkey, Republic of Turkmenistan Turks and Caicos Islands Tuvalu Uganda, Republic of Ukraine United Arab Emirates United Kingdom of Great Britain & N. Ireland Uruguay, Eastern Republic of Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam, Socialist Republic of Wallis and Futuna Islands Western Sahara Yemen Zambia, Republic of Zimbabwe

Read more:

Supreme Court rejects COVID-19 vaccine appeals from nonprofit founded by Robert F. Kennedy Jr. - Bowling Green Daily News

Longitudinal Follow-Up Study on the Side Effects of COVID-19 Vaccines: A Telephonic Questionnaire Approach – Cureus

June 22, 2024

Specialty

Please choose I'm not a medical professional. Allergy and Immunology Anatomy Anesthesiology Biostatistics Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health Family Medicine Forensic Medicine Gastroenterology General Practice Genetics Geriatrics Health Policy Hematology HIV/AIDS Hospital-based Medicine I'm not a medical professional. Infectious Disease Integrative/Complementary Medicine Internal Medicine Internal Medicine-Pediatrics Medical Education and Simulation Medical Physics Medical Student Nephrology Neurological Surgery Neurology Nuclear Medicine Nutrition Obstetrics and Gynecology Occupational Health Oncology Ophthalmology Optometry Oral Medicine Orthopaedics Osteopathic Medicine Otolaryngology Pain Management Palliative Care Pathology Pediatrics Pediatric Surgery Pharmacology Physical Medicine and Rehabilitation Plastic Surgery Podiatry Preventive Medicine Psychiatry Psychology Pulmonology Radiation Oncology Radiology Rheumatology Substance Use and Addiction Surgery Therapeutics Trauma Urology Miscellaneous

Read the original post:

Longitudinal Follow-Up Study on the Side Effects of COVID-19 Vaccines: A Telephonic Questionnaire Approach - Cureus

Emergent, once giant in the COVID vaccine business, exits Baltimore – The Baltimore Banner

June 22, 2024

Gaithersburg-based Emergent BioSolutions is officially leaving Baltimore after a tumultuous stretch that began when it was forced to ditch hundreds of millions of doses of COVID-19 vaccine over questionable quality standards.

The company had already laid off hundreds of workers and shuttered the Bayview plant in East Baltimore where those bulk doses were produced. And Emergent said Thursday that it would sell its other major Baltimore plant, located in the Carroll-Camden industrial area, to an affiliate of Bora Pharmaceuticals Co. Ltd.

That plant was a fill center where it packaged drugs and therapeutics for market. Officials said all of Emergents 350 workers are expected to join Bora under the $30 million deal.

The decision to sell our Camden manufacturing facility is aligned with our multi-year plan to create a customer focused, leaner and more flexible organization, while we improve overall profitability and raise capital to reduce our debt, Joe Papa, Emergents president and CEO, said in a statement.

The Baltimore Banner thanks its sponsors. Become one.

We are working to ensure a smooth transition to Bora, especially for our Camden team and valued customers, over the coming weeks and months.

The company has been laying off workers and fending off lawsuits from shareholders since its COVID-19 vaccine debacle years ago. The suits claimed the company inflated its stock price while hiding manufacturing problems.

Emergent also faced an inquiry by the Congress Select Subcommittee on the Coronavirus Crisis that showed its problems were deeper than initially disclosed. In all, about 525 million Emergent vaccine doses made had to be discarded, according to the congressional report.

The Biden administration had already canceled the federal contract, signed during the Trump administration, with Emergent to make the COVID vaccine, but the congressional panel said its finding confirmed the decision.

Federal inspectors found the company had insufficient processes and record keeping to ensure that vaccines were being made properly. Officials said at the time that the massive deals to make two kinds of vaccines at once, those developed by AstraZeneca and Johnson & Johnson, ended up being unrealistic.

The Baltimore Banner thanks its sponsors. Become one.

Johnson & Johnsons vaccine never caught on, and AstraZenecas was largely used overseas.

The company continues to employ workers elsewhere across the U.S., including in Maryland, and Canada, although other Emergent facilities have laid off hundreds of workers in recent years. That includes some 300 layoffs earlier this year when it said it would shutter the Bayview plant and another one based in Rockville. Last year, Emergent laid off about 230 workers in Maryland.

Emergents biggest product continues to be Narcan nasal spray, used to reverse opioid overdoses. It also has government contracts to produce smallpox and anthrax vaccines for the national stockpile.

The Camden deal is expected to close in the third quarter of 2024.

In May, the company reported first quarter income of $9 million on about $300.4 million in revenue.

The Baltimore Banner thanks its sponsors. Become one.

The companys stock price, which peaked at $133 a share in 2020, was at about $6.38 in morning trading.

Correction: This story has been updated to correct the number of Emergents layoffs from earlier this year.

More:

Emergent, once giant in the COVID vaccine business, exits Baltimore - The Baltimore Banner

Dear Abby: My tenant isn’t vaccinated for COVID, what do I do? – New York Post

June 22, 2024

DEAR ABBY: Several months ago, I let the 49-year-old son of a dear friend move into my basement. Jason pays me rent plus utilities.

Last week, he informed me that he is not vaccinated for COVID. He was drinking at the time. Since my husband passed away with COVID in his system two years ago, I told Jason he would need to get vaccinated or find another place to live, but now Im not sure he remembers the conversation.

How should I handle this? I dont want to alienate his mother (or him, whom I love like a son) over this? HEALTH-CONSCIOUS IN COLORADO

DEAR HEALTH-CONSCIOUS: Ask Jason if he remembers the conversation you had in which he mentioned that he has not been vaccinated for COVID. If he doesnt recall having made the statement, remind him. Then tell him that when your husband passed, he had COVID in his system, that you do not want to risk being exposed to COVID and that if he wishes to continue living with you, he will have to stay current on his vaccines. This need not be a confrontation if you approach the subject calmly.

DEAR ABBY: My girlfriend and I broke up after six years. Both of us have children from marriages that ended seven years ago. We reached a point a year and a half ago and started looking for a house together. After realizing we couldnt afford what she wanted in a home for our blended family, our relationship became strained. The last year has been our worst.

As she suffered through job loss and other outside forces affecting her mental health, I tried to offer her more support, but she felt suffocated. I am sometimes too intense trying to find solutions, even when she says she needs space. I have not kept up my end of giving her space.

We have had the best connection of our lives, so seeing her in pain has me distraught. She says she isnt able to give what I need in our relationship, while I have strived to be a good teammate in her times of need. Now she says she is done because I didnt give her space.

She is the love of my life. What do I do during this crushing and devastating time of my life? DAZED IN NORTH CAROLINA

DEAR DAZED: Im sorry things didnt turn out better for you. You and your girlfriend have very different communication styles. She wanted to vent and be heard. You felt compelled to find solutions to her problems. When someone says they need space, it often means the person feels pushed or smothered. It can also mean they want to dial back the relationship or may have met someone else.

Right now, your next step should be a giant one backward. Increase your exercise schedule, spend time with friends and do not sit around alone and brooding over something you cant change. IF the two of you manage to get together again, I urge you to get into couples counseling so this kind of heartbreak doesnt happen again.

Dear Abby is written by Abigail Van Buren, also known as Jeanne Phillips, and was founded by her mother, Pauline Phillips. Contact Dear Abby at DearAbby.com or P.O. Box 69440, Los Angeles, CA 90069.

Follow this link:

Dear Abby: My tenant isn't vaccinated for COVID, what do I do? - New York Post

Vaccination reduces central nervous system IL-1 and memory deficits after COVID-19 in mice – Nature.com

June 20, 2024

Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727733 (2020).

Article CAS PubMed PubMed Central Google Scholar

Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270273 (2020).

Article CAS PubMed PubMed Central Google Scholar

OMahoney, L. L. et al. The prevalence and long-term health effects of long COVID among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine 55, 101762 (2023).

Article PubMed Google Scholar

Han, Q., Zheng, B., Daines, L. & Sheikh, A. Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens 11, 269 (2022).

Article CAS PubMed PubMed Central Google Scholar

Centers for Disease Control and Prevention, National Center for Health Statistics. Long COVIDHousehold Pulse Survey. https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm (2023).

Hua, M. J. et al. Prevalence and characteristics of long COVID 712 months after hospitalization among patients from an urban safety-net hospital: a pilot study. AJPM Focus 2, 100091 (2023).

Article PubMed PubMed Central Google Scholar

Perlis, R. H. et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw. Open 5, e2238804 (2022).

Article PubMed PubMed Central Google Scholar

Taquet, M. et al. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 18, e1003773 (2021).

Article CAS PubMed PubMed Central Google Scholar

Xu, E., Xie, Y. & Al-Aly, Z. Long-term neurologic outcomes of COVID-19. Nat. Med. 28, 24062415 (2022).

Article CAS PubMed PubMed Central Google Scholar

Mehandru, S. & Merad, M. Pathological sequelae of long-haul COVID. Nat. Immunol. 23, 194202 (2022).

Article CAS PubMed PubMed Central Google Scholar

Mndez, R. et al. Long-term neuropsychiatric outcomes in COVID-19 survivors: a 1-year longitudinal study. J. Intern. Med. 291, 247251 (2022).

Article PubMed Google Scholar

Douaud, G. et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature 604, 697707 (2022).

Hampshire, A. et al. Cognitive deficits in people who have recovered from COVID-19. EClinicalMedicine 39, 101044 (2021).

Article PubMed PubMed Central Google Scholar

Guo, P. et al. COVCOG 2: cognitive and memory deficits in long COVID: a second publication from the COVID and cognition study. Front. Aging Neurosci. 14, 804937 (2022).

Article CAS PubMed PubMed Central Google Scholar

Graham, E. L. et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized COVID-19 long haulers. Ann. Clin. Transl. Neurol. 8, 10731085 (2021).

Article CAS PubMed PubMed Central Google Scholar

Monje, M. & Iwasaki, A. The neurobiology of long COVID. Neuron 110, 34843496 (2022).

Article CAS PubMed PubMed Central Google Scholar

Klein, R. S. Mechanisms of coronavirus infectious disease 2019-related neurologic diseases. Curr. Opin. Neurol. 35, 392398 (2022).

Article CAS PubMed PubMed Central Google Scholar

Soung, A. L. et al. COVID-19 induces CNS cytokine expression and loss of hippocampal neurogenesis. Brain 145, 41934201 (2022).

Article PubMed PubMed Central Google Scholar

Grant, R. A. et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature 590, 635641 (2021).

Article CAS PubMed PubMed Central Google Scholar

Schwabenland, M. et al. Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microgliaT-cell interactions. Immunity 54, 15941610 (2021).

Article CAS PubMed PubMed Central Google Scholar

Jensen, M. P. et al. Neuropathological findings in two patients with fatal COVID-19. Neuropathol. Appl. Neurobiol. 47, 1725 (2021).

Article CAS PubMed Google Scholar

Matschke, J. et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 19, 919929 (2020).

Article CAS PubMed PubMed Central Google Scholar

Thakur, K. T. et al. COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital. Brain 144, 26962708 (2021).

Bird, C. M. & Burgess, N. The hippocampus and memory: insights from spatial processing. Nat. Rev. Neurosci. 9, 182194 (2008).

Article CAS PubMed Google Scholar

Zemla, R. & Basu, J. Hippocampal function in rodents. Curr. Opin. Neurobiol. 43, 187197 (2017).

Article CAS PubMed PubMed Central Google Scholar

Basu, J. & Siegelbaum, S. A. The corticohippocampal circuit, synaptic plasticity, and memory. Cold Spring Harb. Perspect. Biol. 7, a021733 (2015).

Article PubMed PubMed Central Google Scholar

Toda, T., Parylak, S. L., Linker, S. B. & Gage, F. H. The role of adult hippocampal neurogenesis in brain health and disease. Mol. Psychiatry 24, 6787 (2019).

Article CAS PubMed Google Scholar

Kumar, A., Pareek, V., Faiq, M. A., Ghosh, S. K. & Kumari, C. Adult neurogenesis in humans: a review of basic concepts, history, current research, and clinical implications. Innov. Clin. Neurosci. 16, 3037 (2019).

CAS PubMed PubMed Central Google Scholar

Hein, A. M. et al. Sustained hippocampal IL-1 overexpression impairs contextual and spatial memory in transgenic mice. Brain Behav. Immun. 24, 243253 (2010).

Article CAS PubMed Google Scholar

Wu, M. D. et al. Adult murine hippocampal neurogenesis is inhibited by sustained IL-1 and not rescued by voluntary running. Brain Behav. Immun. 26, 292300 (2012).

Article CAS PubMed Google Scholar

Soung, A. L. et al. IL-1 reprogramming of adult neural stem cells limits neurocognitive recovery after viral encephalitis by maintaining a proinflammatory state. Brain Behav. Immun. 99, 383396 (2022).

Article CAS PubMed Google Scholar

Garber, C. et al. Astrocytes decrease adult neurogenesis during virus-induced memory dysfunction via IL-1. Nat. Immunol. 19, 151161 (2018).

Article CAS PubMed PubMed Central Google Scholar

Schulthei, C. et al. The IL-1, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep. Med. 3, 100663 (2022).

Article PubMed PubMed Central Google Scholar

Catal, M. et al. The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir. Med. 12, 225236 (2024).

Article PubMed Google Scholar

Al-Aly, Z., Bowe, B. & Xie, Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat. Med. 28, 14611467 (2022).

Article CAS PubMed PubMed Central Google Scholar

Huapaya, J. A. et al. Vaccination ameliorates cellular inflammatory responses in SARS-CoV-2 breakthrough infections. J. Infect. Dis. 228, 4658 (2023).

Article CAS PubMed PubMed Central Google Scholar

Zhu, X. et al. Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study. Lancet Microbe 4, e692e703 (2023).

Article CAS PubMed PubMed Central Google Scholar

Fan, Q. et al. Clinical characteristics and immune profile alterations in vaccinated individuals with breakthrough Delta SARS-CoV-2 infections. Nat. Commun. 13, 3979 (2022).

Article CAS PubMed PubMed Central Google Scholar

Vanderheiden, A. et al. CCR2 signaling restricts SARS-CoV-2 infection. mBio 12, e0274921 (2021).

Article PubMed Google Scholar

Shuai, H. et al. Emerging SARS-CoV-2 variants expand species tropism to murines. EBioMedicine 73, 103643 (2021).

Article CAS PubMed PubMed Central Google Scholar

Pan, T. et al. Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route. Signal Transduct. Target. Ther. 6, 420 (2021).

Article CAS PubMed PubMed Central Google Scholar

Leger, M. et al. Object recognition test in mice. Nat. Protoc. 8, 25312537 (2013).

Article CAS PubMed Google Scholar

Vasek, M. J. et al. A complementmicroglial axis drives synapse loss during virus-induced memory impairment. Nature 534, 538543 (2016).

Article CAS PubMed PubMed Central Google Scholar

Rosen, S. F. et al. Single-cell RNA transcriptome analysis of CNS immune cells reveals CXCL16/CXCR6 as maintenance factors for tissue-resident T cells that drive synapse elimination. Genome Med. 14, 108 (2022).

Article CAS PubMed PubMed Central Google Scholar

Brannock, M. D. et al. Long COVID risk and pre-COVID vaccination in an EHR-based cohort study from the RECOVER program. Nat. Commun. 14, 2914 (2023).

Article CAS PubMed PubMed Central Google Scholar

Notarte, K. I. et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. EClinicalMedicine 53, 101624 (2022).

Article PubMed PubMed Central Google Scholar

Bricker, T. L. et al. A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. Cell Rep. 36, 109400 (2021).

Article CAS PubMed PubMed Central Google Scholar

Antunes, M. & Biala, G. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn. Process. 13, 93110 (2012).

Article CAS PubMed Google Scholar

Yang, A. C. et al. Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature 595, 565571 (2021).

Article CAS PubMed PubMed Central Google Scholar

Fullard, J. F. et al. Single-nucleus transcriptome analysis of human brain immune response in patients with severe COVID-19. Genome Med. 13, 118 (2021).

Article CAS PubMed PubMed Central Google Scholar

Lee, M. H. et al. Neurovascular injury with complement activation and inflammation in COVID-19. Brain 145, 25552568 (2022).

Article PubMed Google Scholar

Lage, S. L. et al. Persistent oxidative stress and inflammasome activation in CD14highCD16 monocytes from COVID-19 patients. Front. Immunol. 12, 799558 (2021).

More here:

Vaccination reduces central nervous system IL-1 and memory deficits after COVID-19 in mice - Nature.com

Cancer Patients Develop Fewer Protective Antibodies to COVID-19 – Technology Networks

June 20, 2024

Register for free to listen to this article

Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Researchers from the Institut dInvestigaci en Atenci Primria Jordi Gol (IDIAPJGol) and the Barcelona Institute for Global Health (ISGlobal), a center promoted by la Caixa Foundation, have led astudy on the effectiveness of vaccines against COVID-19 among cancer patientsin Catalonia. Theresearch, recently published in the journalNature Communications,recommends administering additional doses of the vaccine among this risk population.

Cancer patientsare atincreased risk of death from COVID-19,especially those who have lung cancer, hematological malignancies or are undergoing systemic treatment, such as chemotherapy.

Theparticipationof patients with active cancer inclinical trialsthat have been carried out to test the effectiveness of vaccines against COVID-19 has been verylimited, so it has not been possible to know exactly the effectiveness of immunization against the SARS-CoV-2 virus among this risk group.

However,prospective datafrom several studies show thatcancer patients may develop fewer protective antibodiesto COVID-19 virus than the general population, especially after receiving a single dose of the vaccine.

The study that has just been published inNature Communicationsconfirms these results, based on theanalysis of massive data obtained from clinical registries. This is themost comprehensive work yet on this issueand thefirstof this kind withinformation from real-world data, providing a more realistic view of how vaccines are working in everyday clinical practice among people with cancer.

The researchers have analyzed the data of184,744 patientswith neoplasia included in the information system for the development of research in primary care (SIDIAP), the database that includes people treated at the first level of care in Catalonia. Half of the individuals included in the study (92,372) had received at least the first complete immunization (two inoculations of the vaccine) and the other half (92,372) had not been vaccinated at the time of the work.

Subscribe to Technology Networks daily newsletter, delivering breaking science news straight to your inbox every day.

The results of the study show that therate of mortality and serious complications among cancer patients not vaccinated against COVID-19 is twicethat of those who have received the full first dose. However, this difference is smaller than the observed data among the general population immunized against SARS-CoV-2 and the non-immunized population.

Our results clearly demonstrate that vaccination against COVID-19 significantly reduces mortality and serious complications among cancer patients,especially those who have received the booster dose, highlighted ISGlobal researcherOtavio Ranzani, who supervised the study together withTalita Duarte-Sallsfrom IDIAPJGol.

For her part, this researcher explained that this work provides essential information to understand the impact of vaccination against COVID-19 on cancer patients, and helps to design public health policies that protect this vulnerable population.

Reference:Lazar Neto F, Mercad-Besora N, Ravents B, et al. Effectiveness of COVID-19 vaccines against severe COVID-19 among patients with cancer in Catalonia, Spain. Nat Commun. 2024;15(1):5088. doi: 10.1038/s41467-024-49285-y

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.

Originally posted here:

Cancer Patients Develop Fewer Protective Antibodies to COVID-19 - Technology Networks

Page 16«..10..15161718..3040..»